Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

Specific immunologic reagent tests have been identified with these reactions, and, in some cases, the concentrations needed to elicit the reaction were provided. Rifampin is another antiinfective ...

Aspartate transaminase, alanine transaminase (ALT), total cholesterol, LDL cholesterol and HDL cholesterol were determined using a COBAS-MIRA+ biochemical analyser ... Total RNA was extracted with ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...